Video Experimental Relacionado
Updated: May 6, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
11.7K
El estradiol acelera la reendotelización en la arteria carótida del ratón a través del receptor de estrógeno alfa,
L Brouchet1, A Krust, S Dupont
1INSERM U397, Institut L. Bugnard, CHU Rangueil, Toulouse, France.
Circulation
|February 7, 2001
Resumen
El 17beta-estradiol (E(2) acelera la reendotelialización, un proceso clave en la prevención de la aterosclerosis. Este efecto beneficioso está mediado por el receptor de estrógeno alfa (ERalpha), no ERbeta, en ratones.
Área de la Ciencia:
- Biología Cardiovascular Biología Cardiovascular
- Endocrinología Endocrinología.
- Biología Vascular Biología Vascular
Sus antecedentes:
- El 17beta-estradiol (E(2) exhibe efectos ateroprotectores en mujeres y animales.
- E(2) influye en el metabolismo de los lípidos y tiene un impacto directo en las células de la pared arterial.
- Los estudios demuestran que E(2) mejora la relajación dependiente del endotelio y la reendotelialización.
Objetivo del estudio:
- Para investigar los mecanismos moleculares de la reendotelialización mediada por E(2) en ratones.
- Evaluar el papel de los receptores de estrógenos (ERalfa y ERbeta) en el efecto de E2 sobre la reparación vascular.
Principales métodos:
- Desarrolló un modelo de lesión carotídea eléctrica en ratones para evaluar la reendotelialización.
- Utilizó ratones silvestres hembras castradas y ratones transgénicos ovariectomizados que carecían de ERalpha o ERbeta.
- Administrado E(2) para evaluar su impacto en la regeneración endotelial.
Principales resultados:
- E(2) aceleró significativamente la regeneración endotelial en ratones de tipo salvaje.
- E(2) promovió la reendotelialización en ratones knockout de ERbeta.
- El efecto pro-regenerativo de E(2) fue abolido en ratones knockout ERalpha.
Conclusiones:
- El receptor de estrógenos alfa (ERalpha) es el principal mediador de los efectos beneficiosos de E(2) sobre la reendotelialización.
- ERalpha juega un papel crucial en la prevención potencial de la aterosclerosis por E.
- La ERbeta no parece mediar los efectos de la E2 sobre la reendotelialización.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:30Adrenergic Agonists: Direct-Acting Agents
2.8K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.8K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
619
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619